Stockscreener 앱 받기
7.51
6.52%
0.46
시간 외 거래:
7.54
0.03
+0.40%
전일 마감가:
$7.05
열려 있는:
$7
하루 거래량:
181.15K
Relative Volume:
0.46
시가총액:
$84.02M
수익:
$3.57M
순이익/손실:
$-7.80M
주가수익비율:
-7.7399
EPS:
-0.9703
순현금흐름:
$-6.56M
1주 성능:
+7.44%
1개월 성능:
+42.23%
6개월 성능:
+173.09%
1년 성능:
+242.92%
1일 변동 폭
$6.91
$7.80
1주일 범위
$6.04
$7.97
52주 변동 폭
$1.33
$7.97
Neuraxis Inc Stock (NRXS) Company Profile
명칭
Neuraxis Inc
전화
(812) 689-0791
주소
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.51 | 78.87M | 3.57M | -7.80M | -6.56M | -0.9703 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Neuraxis Inc 주식(NRXS)의 최신 뉴스
Treasury Yields: Should I trade or invest in NeurAxis Inc2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth - TradingView
NeurAxis Shares Rise After Q4 Results Driven by Robust Revenue Expansion - Bitget
If You Invested $1,000 in Neuraxis Inc (NRXS) - Stock Titan
Craig Hallum Increases NeurAxis (NASDAQ:NRXS) Price Target to $13.00 - Defense World
Dip Buying: Can NeurAxis Inc outperform under higher oil prices2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Gainers Report: Can NeurAxis Inc expand its profit marginsEarnings Beat & AI Powered Market Entry Ideas - baoquankhu1.vn
Neuraxis, Inc.: Fundamental Analysis and Financial Ratings | NRXS | US64134X2018 - marketscreener.com
NeurAxis (NASDAQ:NRXS) Given New $13.00 Price Target at Craig Hallum - MarketBeat
NeurAxis Earnings Call: Reimbursement Wins Drive Next Phase - TipRanks
Earnings call transcript: NeurAxis Q4 2025 sees revenue growth, stock dips - Investing.com Australia
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NeurAxis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
NRXS: FY2025 revenue rose 33% to $3.6M, with improved net loss and expanded market access - TradingView
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Neuraxis 10-K: $3.57M Revenue, $(7.80)M Net Loss - TradingView
NeurAxis says its pain-treatment device now reaches 100M insured lives - Stock Titan
Neuraxis (NRXS) expands IB-Stim GI neuromodulation, RED constipation device and IP moat - Stock Titan
Levels Update: Should I trade or invest in NeurAxis Inc2026 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC) - The Globe and Mail
Aug Ideas: What is the implied volatility of NeurAxis Inc2026 Fed Impact & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
NeurAxis, Inc. Hits New 52-Week High of $7.46, Up 141.44% - Markets Mojo
Breakout Zone: Is NeurAxis Inc impacted by rising ratesTrade Exit Report & Stock Portfolio Risk Control - baoquankhu1.vn
NeurAxis, Inc. Hits New 52-Week High at USD 7.34 - Markets Mojo
Neuraxis price target raised to $8 from $7 at Craig-Hallum - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 - Sahm
Medical tech firm NeurAxis schedules March 19 call on 2025 results - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
NeurAxis (NASDAQ:NRXS) Shares Up 0.7%Still a Buy? - MarketBeat
NeurAxis, Inc. Hits New 52-Week High of $6.35, Up 98.97% - Markets Mojo
Volume Recap: Can TTWO expand its profit marginsJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How FlexShares iBoxx 3 Year Target stock trades in high volatilityMarket Activity Summary & Reliable Price Breakout Signals - Naître et grandir
Update Recap: Should you avoid OSCR stock right now2025 Macro Impact & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Highlights: Can NeurAxis Inc stock outperform in a bear marketJuly 2025 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Chronic Idiopathic Constipation Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland - Barchart.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
00152 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeurAxis, Inc. Hits New 52-Week High of $6.30, Up 115.75% - Markets Mojo
S32 Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BPCF Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neuraxis (NRXS) awards 47,569 RSUs to senior executive Miranda - Stock Titan
P 500Share Buyback & Expert Approved Trade Ideas - mfd.ru
NRXS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Director at Neuraxis (NRXS) receives 21,598-share equity grant as compensation - Stock Titan
Neuraxis (NRXS) CEO granted 94,173 RSUs in three-year vesting award - Stock Titan
Director at Neuraxis (NRXS) receives 21,598-share stock grant as compensation - Stock Titan
SMN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LINK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Neuraxis Inc (NRXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):